|
|
|
|
|
|
|
|
|
|
|
13.04.26 - 23:51
|
UL Solutions Inc. Broadens Portfolio with Agreement to Acquire Eurofins Scientific′s Electrical & Electronics Business (Business Wire)
|
|
|
Expands UL Solutions' global laboratory footprint and enhances commitment to TIC services for electrical safety and connected products
Transaction expected to close in Q4 2026 subject to regulatory approvals and customary closing conditionsNORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced it has entered into a definitive agreement to acquire the electrical and electronics (E&E) business (inclusive of the MET Labs certification mark) of Eurofins Scientific SE (“Eurofins”).1
The transaction expands UL Solutions' global footprint and is intended to enhance its testing, inspection and certification (TIC) business for electrical safety and connected products.
Purchase price represents an enterprise value of approximately €575 million (approximately $670 million).
Expected to be funded with cash on hand, including proceeds from the sale of the Company's Employee Health and Safety software business, and available capacity on the ...
|
|
|
13.04.26 - 22:33
|
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis′ Allogeneic CAR-T Platform (GlobeNewswire EN)
|
|
|
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today highlights the interim futility analysis announced by Allogene Therapeutics, Inc. (“Allogene”) from Allogene's sponsored pivotal ALPHA3 trial evaluating cema-cel in first-line consolidation for large B-cell lymphoma (LBCL). Cema-cel is a product candidate licensed to Servier under the License, Development and Commercialization Agreement signed by and between les Laboratoires Servier and Institut de Recherches Internationales Servier (“Servier”) and Cellectis (the “Servier Agreement”) and sublicenced by Servier to Allogene in certain territories....
|
|
|
13.04.26 - 22:21
|
UL Solutions Inc. Broadens Portfolio with Agreement to Acquire Eurofins Scientific′s Electrical & Electronics Business1 (Business Wire)
|
|
|
Expands UL Solutions' global laboratory footprint and enhances commitment to TIC services for electrical safety and connected products
Transaction expected to close in Q4 2026 subject to regulatory approvals and customary closing conditionsNORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced it has entered into a definitive agreement to acquire the electrical and electronics (E&E) business (inclusive of the MET Labs certification mark) of Eurofins Scientific SE (“Eurofins”).
The transaction expands UL Solutions' global footprint and is intended to enhance its testing, inspection and certification (TIC) business for electrical safety and connected products.
Purchase price represents an enterprise value of approximately €575 million (approximately $670 million).
Expected to be funded with cash on hand, including proceeds from the sale of the Company's Employee Health and Safety software business, and available capacity on the C...
|
|
|
|
|
|
|
|
|
|
|
|
|
13.04.26 - 07:03
|
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#Actionnaires--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 21, 2026, at its headquarters, 117 avenue de Luminy, 13009 Marseille.
The notice of meeting for this AGM was published on April 13, 2026 in the French Bulletin des annonces légales obligatoires (BALO). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.
Documents and information relating to the AGM will be made available to shareholders in compliance with current regulations on the Investors section of the Company's website.
The AGM will also be broadcast live and accessible at the following link: Innate Pharma 2026 Annual General Meeting
A guided tour of the Company's laboratories will be organized on the same day at 9:15 a.m. CEST for shareholders. Shareholders can register for the tour via the follo...
|
|
|
|
|
10.04.26 - 20:06
|
Sanofi Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi vor Quartalszahlen auf "Neutral" mit einem Kursziel von 95 Euro belassen. Seine Gewinnprognose für das erste Jahresviertel liege 4 Prozent über der Konsensschätzung, schrieb ......
|
|
|
|
|
|
|
10.04.26 - 12:01
|
Sanofi Neutral (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Sanofi mit einem Kursziel von 88 Euro auf "Neutral" belassen. Analyst Matthew Weston rechnet in seinem Ausblick auf den Quartalsbericht am 23. April mit massivem Währungsgegenwind. ......
|
|
|
|
|
09.04.26 - 18:03
|
Availability of Transgene′s 2025 Universal Registration Document (URD) (GlobeNewswire EN)
|
|
|
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
